Guggenheim Cuts PT On Perrigo (PRGO) By 30%

Go back to Guggenheim Cuts PT On Perrigo (PRGO) By 30%

Ackman, Valeant pledge reforms after spiking drug prices

April 27, 2016 12:13 AM EDT

By Sarah N. Lynch and Bill Berkrot

WASHINGTON/NEW YORK (Reuters) - Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals (NYSE: VRX) to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.

Speaking before the Senate Special Committee on Aging, Ackman revealed that Valeant's board will hold a conference call on Thursday to discuss the costs of heart medications Isuprel and Nitropress, as well as Cuprimine and Syprine, two drugs... More

It's Too Early To Buy Perrigo (PRGO) - RBC

April 26, 2016 8:28 AM EDT

RBC Capital analyst, Randall Stanicky, cut his target on Perrigo Co. (NYSE: PRGO) to $109 from $140 as the estimate cuts overshadow even the loss of a CEO. No change to Sector Perform rating.

The departure of CEO Joe Papa to join VRX wasn't... More

Perrigo (PRGO) Declares $0.145 Quarterly Dividend; 0.6% Yield

April 26, 2016 8:26 AM EDT

Perrigo (NYSE: PRGO) declared a quarterly dividend of $0.145 per share, or $0.58 annualized.

The dividend will be payable on June 14, 2016, to stockholders of record on May 27, 2016, with an ex-dividend date of May 25, 2016.

The annual yield on the dividend is 0.6 percent.

For a... More